ArticleJournal of nanobiotechnology2026
Microneedle patches deliver targeted GLP-1RAs-loaded nanoparticles for the treatment of rheumatoid arthritis.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
Despite the strong immune-modulatory benefits, there has been a lag in using glucagon-like peptide-1 receptor agonists (GLP-1RAs) in rheumatoid arthritis (RA) due to inefficient articular delivery and poorly understood direct cartilage protection. In this paper, we addressed these critical issues through the mechanism-informed design of a hierarchical drug delivery system. We elucidated previously unnoted ways in which GLP-1RAs curbed RA pathology via direct suppression of the cGAS-STING signaling pathway to inhibit chondrocyte ferroptosis and concomitantly induced macrophage M2 polarization. To turn this mechanistic insight into a targeted therapy, we developed cartilage-targeting silk fibroin nanoparticles modified with a type II collagen-binding peptide WYRGRL for localized GLP-1RAs delivery (GLP-1RAs@NPs-WYRGRL). These GLP-1RAs@NPs-WYRGRL were subsequently loaded into dissolving microneedles (MNs) patches, giving a composite MNs/GLP-1RAs@NPs-WYRGRL system. This system enabled painless transdermal delivery with marked accumulation in arthritic joints, which effectively inhibited chondrocyte ferroptosis via the aforementioned mechanism and also promoted macrophage M2 polarization, thereby attenuating RA progression. This study not only found that the cGAS-STING-ferroptosis pathway was a druggable target in joints, but also pioneered a new flexible delivery platform that resolved the key limitation of low local drug concentrations in joints after systemic administration, and offered a cartilage-protecting perspective for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.